Proteins with Altered Levels in Plasma from Glioblastoma Patients as Revealed by iTRAQ-Based Quantitative Proteomic Analysis

Glioblastomas (GBMs) are the most common and lethal primary tumors of the central nervous system with high level of recurrence despite aggressive therapy. Tumor-associated proteins/peptides may appear in the plasma of these patients as a result of disruption of the blood-brain barrier in them, raising the scope for development of plasma-based tests for diagnosis and monitoring the disease. With this objective, we analyzed the levels of proteins present in the plasma from GBM patients using an iTRAQ based LC-MS/MS approach. Analysis with pooled plasma specimens from the patient and healthy control samples revealed high confidence identification of 296 proteins, of which 61 exhibited a fold-change ≥1.5 in the patient group. Forty-eight of them contained signal sequence. A majority have been reported in the differentially expressed transcript or protein profile of GBM tissues; 6 have been previously studied as plasma biomarkers for GBM and 16 for other types of cancers. Altered levels of three representative proteins–ferritin light chain (FTL), S100A9, and carnosinase 1 (CNDP1)–were verified by ELISA in a test set of ten individual plasma specimens. FTL is an inflammation marker also implicated in cancer, S100A9 is an important member of the Ca2+ signaling cascade reported to be altered in GBM tissue, and CNDP1 has been reported for its role in the regulation of the levels of carnosine, implicated as a potential drug for GBM. These and other proteins in the dataset may form useful starting points for further clinical investigations for the development of plasma-based biomarker panels for GBM.

[1]  D. Cheresh,et al.  Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. , 1991, The Journal of clinical investigation.

[2]  R. Divella,et al.  Epidermal Growth Factor Receptor Serum Levels and Prognostic Value in Malignant Gliomas , 2007, Tumori.

[3]  H. Ozawa,et al.  Development of ferritin-positive cells in cerebrum of human brain. , 1994, Pediatric neurology.

[4]  J. Stewart,et al.  CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. , 2005, Cancer research.

[5]  Ganesh Rao,et al.  The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. , 2011, Genes & development.

[6]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[7]  R. Sherwood,et al.  Serum carnosinase activities in central nervous system disorders. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[8]  Margaret Wrensch,et al.  Epidemiology and molecular pathology of glioma , 2006, Nature Clinical Practice Neurology.

[9]  Bin Hu,et al.  Fibulin-3 Is Uniquely Upregulated in Malignant Gliomas and Promotes Tumor Cell Motility and Invasion , 2009, Molecular Cancer Research.

[10]  H. Mehdorn,et al.  Glioblastoma multiforme-report of 267 cases treated at a single institution. , 2005, Surgical neurology.

[11]  R. Veltri,et al.  Serum ferritin as a tumor marker in patients with squamous cell carcinoma of the head and neck , 1986, Cancer.

[12]  S. Pizzo,et al.  Immunohistochemical Detection of Factor VIII/von Willebrand Factor in Hyperplastic Endothelial Cells in Glioblastoma Multiforme and Mixed Glioma‐Sarcoma , 1982, Journal of neuropathology and experimental neurology.

[13]  Haowen Jiang,et al.  Serum protein profiling to identify biomarkers for small renal cell carcinoma. , 2010, Indian journal of biochemistry & biophysics.

[14]  E. Vollmer,et al.  MRP8 and MRP14, S-100-like proteins associated with myeloid differentiation, are translocated to plasma membrane and intermediate filaments in a calcium-dependent manner. , 1993, Blood.

[15]  Akhilesh Pandey,et al.  LC-MS/MS Analysis of Differentially Expressed Glioblastoma Membrane Proteome Reveals Altered Calcium Signaling and Other Protein Groups of Regulatory Functions* , 2012, Molecular & Cellular Proteomics.

[16]  H. Schluesener,et al.  Expression and release of CD14 in astrocytic brain tumors , 2003, Acta Neuropathologica.

[17]  Richard D. Smith,et al.  Establishing the Proteome of Normal Human Cerebrospinal Fluid , 2010, PloS one.

[18]  P. Chyou,et al.  Association of serum ferritin levels with the risk of stomach cancer. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[19]  L. Deangelis,et al.  YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas , 2006, Clinical Cancer Research.

[20]  F. Altruda,et al.  Hemopexin: structure, function, and regulation. , 2002, DNA and cell biology.

[21]  I. Modlin,et al.  Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease , 2010, Annals of Surgical Oncology.

[22]  V. Vila,et al.  Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma , 2011, Journal of Neuro-Oncology.

[23]  Vani Santosh,et al.  Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. , 2010, Journal of proteome research.

[24]  F. Howe,et al.  Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. , 2008, Clinical chemistry.

[25]  H. Steinmetz,et al.  Serum GFAP is a diagnostic marker for glioblastoma multiforme. , 2007, Brain : a journal of neurology.

[26]  H. Kwaan,et al.  The role of plasminogen-plasmin system in cancer. , 2009, Cancer treatment and research.

[27]  H. Haapasalo,et al.  Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors , 2010, BMC Cancer.

[28]  J. Lenney,et al.  Homocarnosinosis: lack of serum carnosinase is the defect probably responsible for elevated brain and CSF homocarnosine. , 1983, Clinica chimica acta; international journal of clinical chemistry.

[29]  A. Paetau,et al.  Lymphocyte adhesion molecule ligands and extracellular matrix proteins in gliomas and normal brain: expression of VCAM-1 in gliomas , 1997, Acta Neuropathologica.

[30]  P. Angel,et al.  Dual Role of S100A8 and S100A9 in Inflammation-Associated Cancer , 2009 .

[31]  Yoshihiro Sato,et al.  Cerebrospinal fluid ferritin in glioblastoma: Evidence for tumor synthesis , 1998, Journal of Neuro-Oncology.

[32]  Connie R. Jimenez,et al.  iTRAQ-based Proteomics Profiling Reveals Increased Metabolic Activity and Cellular Cross-talk in Angiogenic Compared with Invasive Glioblastoma Phenotype* , 2009, Molecular & Cellular Proteomics.

[33]  P. Gasque,et al.  Expression of complement components of the alternative pathway by glioma cell lines. , 1992, Journal of immunology.

[34]  M. Skinner,et al.  Acute‐Phase Proteins or Tumour Markers: The Role of SAA, SAP, CRP and CEA as Indicators of Metastasis in a Broad Spectrum of Neoplastic Diseases , 1984, Scandinavian journal of immunology.

[35]  F. Gaunitz,et al.  Carnosine and cancer: a perspective , 2012, Amino Acids.

[36]  Y. Matsukado,et al.  Immunohistochemical localization of apolipoprotein E in human glial neoplasms. , 1988, Journal of Clinical Investigation.

[37]  P. Bracci,et al.  Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma. , 2010, Cancer research.

[38]  T. de Boer,et al.  Serum carnosinase activity in plasma and serum: validation of a method and values in cardiopulmonary bypass surgery. , 2003, Clinical chemistry.

[39]  H. Haapasalo,et al.  Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. , 2007, Neuro-oncology.

[40]  L. Deangelis,et al.  Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. , 2011, Neuro-oncology.

[41]  R. Aebersold,et al.  A High-Confidence Human Plasma Proteome Reference Set with Estimated Concentrations in PeptideAtlas* , 2011, Molecular & Cellular Proteomics.

[42]  Erwin G. Van Meir,et al.  Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers , 2006, Proteomics.

[43]  S. Belli,et al.  Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina. , 2009, Acta gastroenterologica Latinoamericana.

[44]  B. Scheithauer,et al.  Expression of diagnostic neuronal markers and outcome in glioblastoma , 2010, Neuropathology and applied neurobiology.

[45]  I. Modlin,et al.  The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. , 2011, Endocrinology and metabolism clinics of North America.

[46]  A. Silvani,et al.  Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients. , 1999, Cancer letters.

[47]  Thomas Ludwig,et al.  Glioblastoma cells release factors that disrupt blood-brain barrier features , 2004, Acta Neuropathologica.

[48]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[49]  J. Meixensberger,et al.  Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model , 2010, Molecular Cancer.